

Q4FY23 Preview

31 March 2023

Cautious outlook for NBFCs; AMCs, life insurers to fare better

- Expect SBI Life to deliver continued cost efficiency and high margins in
 Q4; remains our top pick among life insurers
- 360 One projected to post 12% YoY AUM growth in Q4 on strong recurring flows, with IIFL One being a major pillar
- Nippon AMC and UTI AMC likely to see a strong quarter; both remain our top picks among asset managers

Mohit Mangal research@bobcaps.in

Life insurance: We maintain a positive stance on the life insurance industry as a focus on profitable non-participating and protection products is expected to help our coverage companies maintain robust VNB margins (SBI Life, HDFC Life, IPRU) in Q4FY23. We project gross premium growth of 16% YoY for top pick SBI Life (BUY, TP Rs 1,459) and a total cost ratio of less than 10% even after baking in an increase of 50-60bps YoY. We believe **budgetary announcements** remain directionally negative for the sector.

Asset management: We are cautious on AMC stocks due to (a) SEBI initiating a detailed study of the fees and expenses charged by mutual funds, and (b) the abrupt removal of long-term tax benefits for debt mutual funds. We had **initiated** on the sector with an upbeat outlook on **UTI AMC** (BUY, TP Rs 983) and **Nippon AMC** (BUY, TP Rs 347). For Q4, we believe a focus on equity funds, SIPs, and higher yielding B-30 cities will continue to drive topline growth whereas cost rationalisation should aid the bottom-line. Commentary on the impact of changing regulations is a key monitorable.

Wealth management: We expect 360 One to post 12% YoY AUM growth in Q4FY23 boosted by fresh fund flows and MTM gains despite high volatility in equity markets. Recurring AUM is forecast to constitute 58% of the mix (55% at end-FY22) with IIFL One being a key pillar. Revenue could be flattish as estimated increases of 13% YoY in recurring revenue and 7% YoY in other income are likely to be offset by a decline in transactional revenue. We expect the company to have a cost-to-income ratio of 44.8% and deliver PAT growth of 3% YoY.

Credit cards: Sectoral credit card spends continued to gain traction in January and February, crossing the Rs 1tn mark in each of these months. SBI Card regained second position and we estimate 16% YoY growth in spends for the company in Q4. Its market share stood at ~20% in credit cards outstanding and ~18% in spends at the end of February. Net receivables are forecast to grow 30% YoY. We believe NIM would take time to return to pre-Covid levels. Provisions are expected to remain low (+30bps YoY, -7bps QoQ), and we place credit cost at 5.7%. Data on operating costs, revolver balances and credit cost would be key to watch.

Recommendation snapshot

		•	
Ticker	Price	Target	Rating
360ONE IN	439	591	BUY
ABSLAMC IN	317	488	HOLD
HDFCAMC IN	1,678	2,310	BUY
HDFCLIFE IN	496	549	HOLD
IPRU IN	427	487	BUY
NAM IN	204	347	BUY
SBICARD IN	720	1,034	BUY
SBILIFE IN	1,099	1,459	BUY
UTIAM IN	616	983	BUY

Price & Target in Rupees | Price as of 29 Mar 2023





Fig 1 – BOBCAPS NBFC universe: Q4FY23 estimates

Company (Rs mn)	Q4FY23E	Q4FY22	Q3FY23	YoY (%)	QoQ (%)	Comments	
NBFC				. ,	. ,		
SBI Card							
Spends	6,26,282	5,41,350	6,88,350	15.7	(9.0)		
Loans	3,92,832	3,01,873	3,73,540	30.1	5.2	We expect 30% YoY loan growth which should positively impact	
NII	11,884	9,987	11,446	19.0	3.8	NII, but NIM is likely to be low on account of weaker revolver balances and a higher cost of funds. Higher operating expenses are likely to offset an increase in revenue which will lead to a YoY decline in the net profit. Data on receivable mix, operating cost and credit cost would be key to watch.	
NIM (%)	11.4	12.6	11.3	(126bps)	5bps		
PPOP	12,652	11,720	12,174	8.0	3.9		
Credit costs (%)	5.7	5.4	5.8	30bps	(7bps)		
PAT	5,441	5,809	5,095	(6.3)	6.8		
360 One WM	-,	-,,,,,	-,,,,,	(515)		ALIMA:	
AUM	29,18,453	26,17,447	27,51,336	11.5	6.1	AUM is projected to grow 11.5% YoY to Rs 2.9tn. However, we	
Total revenue	4,562	4,493	4,096	1.5	11.4	expect net revenue to inch up only 2% despite forecasting 13% YoY growth in recurring revenue, as non-recurring revenue is	
C/I (%)	44.8	52.3	45.5	(750bps)	(66bps)	projected to decline 17%. A likely reduction in cost-to-income ratio	
PAT	1,727	1,678	1,801	2.9	(4.1)	would be a key positive. Commentary around exploring new	
Yield (Overall) (%)	0.60	0.72	0.60	(13bps)	(1bps)	geographies in FY24 would be key to watch.	
Company (Rs mn)	Q4FY23E	Q4FY22	Q3FY23	YoY (%)	QoQ (%)	Comments	
LIFE INSURANCE	4	4	4020	101 (/0)	404 (10)	Comments	
SBI Life						Wa surrest 400/ VeV /50/ OaO) manuficial management and but a	
Gross Premium	2,03,736	1,75,085	1,93,319	16.4	5.4	We expect 16% YoY (5% QoQ) growth in gross premium led by a renewed focus on non-par products and sale of protection	
Total cost (%)	9.6	9.0	9.1	62bps	53bps	products. Cost can continue to remain on the higher side but	
Profit after tax (Shareholder)	9,850	6,722	3,041	46.5	223.9	should still clock in below 10%.	
HDFC Life	<u> </u>	<u> </u>				Should still clock in polow 1076.	
Gross Premium	1,52,542	1,44,213	1,45,750	5.8	4.7	Gross premium is expected to rise 6% YoY. We forecast total of	
Total cost (%)	18.1	16.8	19.3	124bps	(121bps)	at 18%, lower than the previous quarter but higher on an annuabasis.	
Profit after tax (Shareholder)	2,672	3,575	3,152	(25.3)	(15.2)		
IPRU				(/	(- /		
Gross Premium	1,19,836	1,17,106	97,805	2.3	22.5	Gross premium is likely to increase 2% YoY with the company	
Total cost (%)	13.6	15.8	14.7	(226bps)	(110bps)	focusing on maintaining a favourable product mix. Total cost looks	
Profit after tax (Shareholder)	3,266	1,847	2,206	76.8	48.0	set to decline both YoY and QoQ.	
Company (Rs mn)	Q4FY23E	Q4FY22	Q3FY23	YoY (%)	QoQ (%)	Comments	
AMC	Q+1 120L	Q(+1 122	Q(3) 123	101 (70)	QUQ (70)	Comments	
Nippon AMC							
AUM (Rs bn)	3,087	2,832	2,928	9.0	5.4	We model for a 9% YoY rise in AUM and the share of equity at	
Total revenue	4,362	3,724	4,157	17.1	4.9	44% vs. 42% in the year-ago quarter. Revenue is expected to	
EBITDA	2,863	2,424	2,752	18.1	4.9	grow 17% YoY, operating expenses at 15% and PAT at a healthy	
PAT	2,003	1,749	2,752	14.8	(2.2)	15%.	
UTIAMC	2,001	1,143	۷,00۷	14.0	(2.2)		
AUM (Rs bn)	2,391	2,238	2,408	6.8	(0.7)	We anticipate a 7% YoY rise in AUM. Revenue is projected to	
Total revenue	3,605	3,050	2,406	18.2	22.9	clock higher growth of 18% YoY as other income likely soars on low base. PAT is expected to more than double YoY driven by higher revenue and a decline in operating expenses.	
EBITDA	1,918	1,244	1,323	54.1	44.9		
PAT	1,718	539	600	218.7	186.3		
HDFC AMC	1,/18	วงษ	000	Z 10.1	100.3		
	4 600	4 204	A AAO	6.0	3.0	We forecast 7% YoY growth in AUM and a 22% increase in revenue as other income rises sharply. PAT is thus expected to	
AUM (Rs bn)	4,620	4,321	4,448	6.9	3.9		
Total revenue	7,082	5,809	6,629	21.9	6.8		
EBITDA	5,807	4,581	5,165	26.8	12.4	grow 18% YoY.	
PAT	4,047	3,436	3,694	17.8	9.6		



Company (Rs mn)	Q4FY23E	Q4FY22	Q3FY23	YoY (%)	QoQ (%)	Comments
ABSL AMC						
AUM (Rs bn)	3,051	2,958	2,817	3.1	8.3	We model for PAT growth in the early double digits, in line with revenue growth. AUM is anticipated to rise 3% YoY and equity in the AUM mix is projected to grow to 42% vs. 41% in the year-ago quarter.
Total revenue	3,816	3,471	3,632	10.0	5.1	
EBITDA	2,459	2,194	2,323	12.1	5.9	
PAT	1,746	1,585	1,663	10.1	5.0	

Source: Company, BOBCAPS Research

Glossary

Glossary of Abbreviations	
AUM: Assets Under Management	B30: Beyond the Top 30 cities
AMC: Asset Management Company	KYC: Know Your Customer
T30: Top 30 cities	MF: Mutual Fund
TER: Total Expense Ratio	SIP: Systematic Investment Plan
APE: Average Premium Equivalent	NBP: New Business Premium
EV: Embedded Value	ULIP: Unit Linked Insurance Plan
IRDA: Insurance Regulatory and Development Authority	VNB: Value of New Business

Source: BOBCAPS Research



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.



The research analyst(s) has not served as an officer, director or employee of the subject company,

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.